| Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies O Abdel-Wahab, A Mullally, C Hedvat, G Garcia-Manero, J Patel, ... Blood, The Journal of the American Society of Hematology 114 (1), 144-147, 2009 | 834 | 2009 |
| Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome S Malinge, S Izraeli, JD Crispino Blood, The Journal of the American Society of Hematology 113 (12), 2619-2628, 2009 | 286 | 2009 |
| The mitochondrial respiratory chain is essential for haematopoietic stem cell function E Ansó, SE Weinberg, LP Diebold, BJ Thompson, S Malinge, ... Nature cell biology 19 (6), 614-625, 2017 | 268 | 2017 |
| Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome S Malinge, M Bliss-Moreau, G Kirsammer, L Diebold, T Chlon, ... The Journal of clinical investigation 122 (3), 948-962, 2012 | 188 | 2012 |
| Activating mutations in human acute megakaryoblastic leukemia S Malinge, C Ragu, V Della-Valle, D Pisani, SN Constantinescu, C Perez, ... Blood, The Journal of the American Society of Hematology 112 (10), 4220-4226, 2008 | 168 | 2008 |
| Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition Q Jeremy Wen, Q Yang, B Goldenson, S Malinge, T Lasho, RK Schneider, ... Nature medicine 21 (12), 1473-1480, 2015 | 152 | 2015 |
| Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia S Malinge, R Ben-Abdelali, C Settegrana, I Radford-Weiss, M Debre, ... Blood 109 (5), 2202-2204, 2007 | 151 | 2007 |
| Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation AA Lane, B Chapuy, CY Lin, T Tivey, H Li, EC Townsend, ... Nature genetics 46 (6), 618-623, 2014 | 147 | 2014 |
| Myeloid leukemia in Down syndrome I Khan, S Malinge, J Crispino Critical Reviews™ in Oncogenesis 16 (1-2), 2011 | 142 | 2011 |
| A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas F Chibon, O Mariani, J Derré, S Malinge, JM Coindre, L Guillou, R Lagacé, ... Cancer genetics and cytogenetics 139 (1), 24-29, 2002 | 121 | 2002 |
| DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3 BJ Thompson, R Bhansali, L Diebold, DE Cook, L Stolzenburg, ... Journal of Experimental Medicine 212 (6), 953-970, 2015 | 87 | 2015 |
| ETO2-GLIS2 hijacks transcriptional complexes to drive cellular identity and self-renewal in pediatric acute megakaryoblastic leukemia C Thirant, C Ignacimouttou, CK Lopez, L Le Mouël, C Thiollier, A Siret, ... Cancer cell 31 (3), 452-465, 2017 | 75 | 2017 |
| A CHAF1B-dependent molecular switch in hematopoiesis and leukemia pathogenesis A Volk, K Liang, P Suraneni, X Li, J Zhao, M Bulic, S Marshall, K Pulakanti, ... Cancer cell 34 (5), 707-723. e7, 2018 | 69 | 2018 |
| Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling S Malinge, C Thiollier, TM Chlon, LC Doré, L Diebold, O Bluteau, ... Blood, The Journal of the American Society of Hematology 121 (13), 2440-2451, 2013 | 60 | 2013 |
| DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3 RS Bhansali, M Rammohan, P Lee, AP Laurent, Q Wen, P Suraneni, ... The Journal of Clinical Investigation 131 (1), 2021 | 56 | 2021 |
| Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes S Malinge, T Chlon, LC Doré, RP Ketterling, MS Tallman, E Paietta, ... Blood, The Journal of the American Society of Hematology 122 (14), e33-e43, 2013 | 53 | 2013 |
| Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome AP Laurent, RS Kotecha, S Malinge Leukemia 34 (8), 1984-1999, 2020 | 51 | 2020 |
| Ontogenic changes in hematopoietic hierarchy determine pediatric specificity and disease phenotype in fusion oncogene–driven myeloid leukemia CK Lopez, E Noguera, V Stavropoulou, E Robert, Z Aid, P Ballerini, ... Cancer discovery 9 (12), 1736-1753, 2019 | 43 | 2019 |
| Activation of the NF-κB pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of antiapoptotic IAP proteins and involves IKKα S Malinge, R Monni, O Bernard, V Penard-Lacronique Oncogene 25 (25), 3589-3597, 2006 | 38 | 2006 |
| Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers A Fagnan, FO Bagger, MR Piqué-Borràs, C Ignacimouttou, A Caulier, ... Blood, The Journal of the American Society of Hematology 136 (6), 698-714, 2020 | 33 | 2020 |
